Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.34-13.3% vs -$0.30 | — vs — |
Q2 2026 May 15, 2026 | -$2.53-803.6% vs -$0.28 | — vs — |
Q2 2026 May 14, 2026 | -$2.53-803.6% vs -$0.28 | — vs — |
Q2 2026 Mar 31, 2026 | -$0.62+0.0% vs -$0.62 | — vs — |
BRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that John W.
What happened Tempest Therapeutics, Inc. (NASDAQ: TPST) said on September 22, 2026, that it signed a Master Services Agreement with Factor Bioscience Inc. The agreement covers research and development services under work orders that both sides approve. Tempest said Work Order No. 1 covers in vivo CAR-T therapies. Effective September 22, 2026, the board appointed
BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the Audit Committee.
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd.
Benchmark TPST against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Tempest Therapeutics, Inc. (TPST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.38 | $5.79M | -0.14 | — | — | -1270.11% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $29.41 | $1.75B | -4.71 | 48.03% | -264.76% | -34.63% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $37.26 | $1.23B | -7.84 | -43.89% | -287.84% | -37.99% | — |
Tempest Therapeutics, Inc. (TPST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Tempest Therapeutics, Inc. (TPST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 18, 2026·SEC
Aug 13, 2026·SEC
Aug 13, 2026·SEC
Get notified when TPST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tempest Therapeutics, Inc. (TPST) stock FAQ — growth, dividends, profitability & financials explained
No. Tempest Therapeutics, Inc. (TPST) reported a net loss of $40.5M over the trailing twelve months.
Tempest Therapeutics, Inc. (TPST) had a return on equity (ROE) of -1270.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
Tempest Therapeutics, Inc. (TPST) had negative free cash flow of $20.7M over the trailing twelve months.
